Identification of mutations in receptor and non-receptor protein kinases that drive malignant transformation of cancer cells ('driver'mutations) have revolutionized patient care by opening the door to patient-tailored targeted therapies that can improve patient survival. In order to discover new targets for therapy, we sequenced the coding regions of -100 melanomas and identified a large number of somatic mutations and inherited Single Nucleotide Variants (SNVs). One of the most important findings of this effort is the identification ofthe "RAC1 signaling pathway" as a potential new target for melanoma therapy. The analysis revealed a recurrent, UV signature activating mutation in this RHO family of small GTPases, RAC[P29S], in ~5% of melanomas, in addition, the sequencing data revealed mutations in upstream regulators and downstream effectors of RAC1 pathway in a large numbers of melanoma tumors. Functional studies demonstrated an important role in proliferation and migration of not only mutant but also melanoma cells that that donot harbor the P29S mutation. The data suggest that pharmacological inhibition of RACl or its critical effeGtor(s) can be applied for development of new therapies for melanoma patients. The general goals ofthis project are to determine the frequency and prognostic significance of RAC[P29S] mutation in sun exposed melanocytic lesions, and to identify downstream effectors of RACl most likely to be druggable targets in this pathway.
The specific aims are:
Aim 1 : To determine the frequency of RAC1[P29S] mutation and RACl expression levels in a large cohort of melanocytic lesions and correlate with pathological features and tumor progression;
Aim 2 : To elucidate the downstream targets of activated RACl in melanomas.
Aim 3 : To identify small-molecule inhibitors of PAK kinases, the RACl effectors. These studies are likely to provide new opportunities for drug discovery for melanomas and possibly other cancers that can facilitate patienttailored targeted therapy.
There is a need for new patient-tailored therapy for melanoma. Treatment of melanoma patients carrying BRAF[V600E/K] mutations with vemurafenib (PLX4032/RG7204), renamed Zelboraf, yields a very high response rate, but the disease tends to relapse. The novel regulatory pathway discovered by exome sequencing and validated by functional analyses provides the opportunity for additional therapeutic targets for patients who do not benefit from current therapies.
|Brash, Douglas E (2016) UV-induced Melanin Chemiexcitation: A New Mode of Melanoma Pathogenesis. Toxicol Pathol 44:552-4|
|Premi, Sanjay; Brash, Douglas E (2016) Chemical excitation of electrons: A dark path to melanoma. DNA Repair (Amst) 44:169-77|
|Jiang, Yu; Shi, Xingjie; Zhao, Qing et al. (2016) Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis. Genomics 107:223-30|
|Cyrus, Nika; Mai-Anh Bui, Christine; Yao, Xiaopan et al. (2016) Density and Polarization States of Tumor-Associated Macrophages in Human Cutaneous Squamous Cell Carcinomas Arising in Solid Organ Transplant Recipients. Dermatol Surg 42 Suppl 1:S18-23|
|Robles-Espinoza, Carla Daniela; Roberts, Nicola D; Chen, Shuyang et al. (2016) Germline MC1R status influences somatic mutation burden in melanoma. Nat Commun 7:12064|
|Gibson, Juliet F; Huang, Jing; Liu, Kristina J et al. (2016) Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-VÎ² chain restriction. J Am Acad Dermatol 74:870-7|
|Wang, Xuefeng; Chen, Mengjie; Yu, Xiaoqing et al. (2016) Global copy number profiling of cancer genomes. Bioinformatics 32:926-8|
|Wang, Yu; Zhao, Yinjun; Ma, Shuangge (2016) Racial differences in six major subtypes of melanoma: descriptive epidemiology. BMC Cancer 16:691|
|Weed, Jason; Gibson, Juliet; Lewis, Julia et al. (2016) FISH Panel for Leukemic CTCL. J Invest Dermatol :|
|Halaban, Ruth; Krauthammer, Michael (2016) RASopathy Gene Mutations in Melanoma. J Invest Dermatol 136:1755-9|
Showing the most recent 10 out of 134 publications